Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

MG731 Bifidobacterium bifidum MG731 and composition for preventing or treating cancers comprising the same

A strain and cancer technology, applied to bacteria used in food preparation, medical preparations containing active ingredients, bacteria, etc., can solve problems such as expensive treatment costs, achieve the effect of reducing mobility and enhancing immune activity

Pending Publication Date: 2019-11-19
GENOME & CO
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still problems as follows: the immune anticancer agent does not show the same anticancer effect on all patients, and the biomarker (biomarker) of the immune anticancer agent has not been clearly disclosed, JAK-STAT gene mutation does not show The effect of drugs, which can lead to autoimmune diseases caused by the properties of antibody complexes, resulting in expensive treatment costs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • MG731 Bifidobacterium bifidum MG731 and composition for preventing or treating cancers comprising the same
  • MG731 Bifidobacterium bifidum MG731 and composition for preventing or treating cancers comprising the same
  • MG731 Bifidobacterium bifidum MG731 and composition for preventing or treating cancers comprising the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0103] Intestinal microbial composition analysis by clinical patient feces

[0104] Feces from 154 normal people and 125 lung cancer patients were received for 16s sequence (16s sequence) analysis to study the composition of intestinal microorganisms. According to the results of the analysis, the patients are classified into pathological categories, and in order to analyze the microorganisms in the intestinal tract based on the classification, they are classified according to the charts of the patients. After classifying only the samples of patients with squamous cell carcinoma and adenocarcinoma, which belong to the two types of non-small cell lung cancer, which are the most common type of non-small cell lung cancer, among the tumor tissues of 125 patients , track the records of patients receiving anticancer drug treatment, and measure the value of tumor size change according to the response to anticancer drug, and use this value as a reference to test the patient's sample ac...

Embodiment 2

[0111] Isolation and cultivation of Bifidobacterium bifidum MG731

[0112] MG731 Strains were isolated from feces of healthy young children using a selective medium for Bifidobacterium spp.

[0113] After the collected stool samples were diluted 10 times in stages in 0.85% NaCl, they were spread on TOS propionate agar (TOS-propionate agar) (Merck Group) added with 50 mg / L mupirocin lithium (lithium mupirocin) (Merck KGaA, Darmstadt, Germany), and after anaerobic culture at a temperature of 37° C. for 48 hours, strains with different colony morphology were screened out. The screened strains were subcultured in a bile lactose medium (BLbroth), and then stored frozen at -80°C in a bile lactose medium (BLbroth) containing 20% ​​glycerol.

[0114] The base sequence of the rRNA of the obtained bacterial strain was analyzed and expressed as SEQ ID NO: 1, and the identification result confirmed that MG731 was Bifidobacterium bifidum. The above-mentioned MG731 strain was deposited in...

Embodiment 3

[0117] Tumor Proliferation Inhibitory Effect of Bifidobacterium bifidum MG731 Strain

[0118] In order to confirm whether Bifidobacterium bifidum MG731 exhibits anti-cancer effects in various cancer cell lines, human cancer cell lines were used for cell viability analysis (MTT assay).

[0119] The cancer cell lines used in cell viability analysis (MTT assay) were lung cancer (A549, H1975, HCC827, H1299, SW900), colorectal cancer (HCT116, LoVo, SNU-C2A, SNU-C1, Colo205), gastric cancer (SNU216, AGS, MKN-28, MKN-1, SNU-601, SNU-1), breast cancer (Hs578T, BT20, MDA-MB-231, MCF7), liver cancer (HepG2, Hep3B) a total of 5 cancer types to experiment.

[0120] Take 1-5×10 3 In the manner of cells / well, the cancer cell line was dispensed into a 96-well plate (96-well plate), and after 24 hours, 1% of the lactic acid bacteria sample was added (1%=12.147 μg, and the concentration of the extract was measured by BCA analysis ), after culturing for 72 hours, MTT (3-(4,5-dimethylthiazol-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for prophylaxis or therapy of cancer, which comprises same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention exhibits effects of inhibiting cancer cell proliferation, decreasing cancer cell motility, suppressing angiogenesis, and increasing anticancer immune responses as well as downregulating the expression of inflammatory factors, thereby preventing or treating cancer or inflammatory diseases. In addition, when used in combination with a chemotherapeutic agent or immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. Further, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for prophylaxis or therapy of cancer, which comprises same. Specifically, the Lactococcus lactis GEN3033 strain of the present invention exhibits the effect of directly inhibiting cancer cell proliferation and enhancing immunity, thereby preventing or treating cancer. Particularly, the strain has an excellent anticancer effect by secreting metabolites having inhibitory activity against cancer while being established in the gut. In addition, when used in combination with a chemotherapeutic agent or an immunotherapeutic agent, the Lactococcus lactis GEN3033 of the present invention exhibits a better anticancer effect.

Description

technical field [0001] The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a Lactococcus lactis GEN3033 strain having excellent effects of preventing or treating cancer. [0002] Specifically, the Bifidobacterium bifidum MG731 strain of the present invention not only has the effect of inhibiting the proliferation of cancer cells, but also has the effect of reducing the mobility of cancer cells and regulating the genes involved in the formation of new blood vessels, thus having a higher effect than the existing two Bifidobacterium fidgetum strains showed significantly excellent results. Moreover, the Bifidobacterium bifidum MG731 bacterial strain of the present invention has anti-inflammatory, anti-oxidation and immune-enhancing effects. [0003] Moreover, the Lactococcus lactis GEN3033 strain of the present invention not only has the growth inhibitory effect of cancer cells themselves, but also enhances the immune activity, thereby having a signi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N1/20A61K35/745A61K35/744A61P35/00C12R1/01
CPCA61K35/745A61K35/744A61P35/00A61K45/06A61P35/02A61P29/00A61P37/04A61P39/06A23L33/135A23C9/1234A23K10/18A23V2002/00A23V2400/157A23V2400/517A61K2300/00A23V2200/308A23V2200/324A23V2200/30A61K35/747C12R2001/46C12N1/205C12R2001/01A61K33/243A61K31/555A61K31/513A61K31/675A61K31/337A23K50/20A23K50/10A23K50/40Y02A50/30C12N1/20A23K10/16A23V2400/231A61K31/282A61K31/475A61K31/519A61K31/704A61K31/7048A61K31/7068A61K39/3955A61K2039/505A61K2039/545C07K16/2818C07K16/2827
Inventor 朴汉洙朴信荣李恩周延济成全蕙熙金元德郑朱然A·R·郑许允景孙珍英金允渊金上均李洙鲁
Owner GENOME & CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com